Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial - sprookjes - yvandenbroek - TriplyDB

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

http://www.wikidata.org/entity/Q24605205

about

Adjuvant radiotherapy following radical prostatectomy for prostate cancer The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer Mechanisms of Progranulin Action and Regulation in Genitourinary Cancers Radiation Therapy after Radical Prostatectomy: Implications for Clinicians Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer Gaps between Evidence and Practice in Postoperative Radiotherapy for Prostate Cancer: Focus on Toxicities and the Effects on Health-Related Quality of Life Rationale and development of image-guided intensity-modulated radiotherapy post-prostatectomy: the present standard of care?Long-term oncologic outcomes of postoperative adjuvant versus salvage radiotherapy in prostate cancer: Systemic review and meta-analysis of 5-year and 10-year follow-up data Optimal management of prostate cancer with lethal biology--state-of-the-art local therapy FROGG high-risk prostate cancer workshop: patterns of practice and literature review. Part II post-radical prostatectomy Management of patients with biochemical recurrence after local therapy for prostate cancer External beam radiotherapy for localized prostate cancer Current clinical challenges in prostate cancer Prostate cancer: ESMO Consensus Conference Guidelines 2012 A Urologist's Personal View of Prostate Cancer How Precisely Can Prostate Cancer Be Managed?Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy Adjuvant and salvage radiotherapy after prostatectomy: a systematic review and meta-analysis.Effect of Preoperative Risk Group Stratification on Oncologic Outcomes of Patients with Adverse Pathologic Findings at Radical Prostatectomy Prognostic outlier genes for enhanced prostate cancer treatment.Reconsidering adjuvant versus salvage radiation therapy for prostate cancer in the genomics era.Adjuvant and salvage radiation therapy after prostatectomy: investigating beliefs and practices of radiation oncologists.Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort.Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy.Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.Implementation of an image guided intensity-modulated protocol for post-prostatectomy radiotherapy: planning data and acute toxicity outcomes.No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy Robot-assisted radical prostatectomy significantly reduced biochemical recurrence compared to retro pubic radical prostatectomy Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery.Counseling patients about sexual health when considering post-prostatectomy radiation treatment.Clinician-led improvement in cancer care (CLICC)--testing a multifaceted implementation strategy to increase evidence-based prostate cancer care: phased randomised controlled trial--study protocol Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer.Shared responsibility for treatment-related morbidity for prostate cancer Adjuvant medical therapy for prostate cancer.Predicting 15-year prostate cancer specific mortality after radical prostatectomy.Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges.Identification of men with the highest risk of early disease recurrence after radical prostatectomy Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.What are the outcomes of radical prostatectomy for high-risk prostate cancer?

P2860

Q24234347-679CC28A-FF27-45EA-A6B1-CAFE81A3792A Q26738703-E0730998-3F0F-4615-995F-5617F8424C8B Q26741917-190C6DF3-3EBC-4988-8E08-D83C961FFD3C Q26744531-07136AB7-49B9-456D-B701-7572E2DDC53A Q26747782-828FA76E-004A-41A2-AEAB-2F77BED7D034 Q26751574-5C9A7B99-ADBB-40CC-8A5D-845EBB867592 Q26774847-0340E3BA-839D-4756-B26B-E1D85D2746C9 Q26777094-8AB1462B-8355-4E38-A021-A0C270118D81 Q26801188-4405DFFC-834A-4F1E-9F6A-08FCA25F7A07 Q26827690-7CD1C042-9538-4136-AA91-A6974CCBA4AB Q26849220-54DD6DBD-02E9-4335-AF94-EFACF05D810B Q26853068-F8F677E6-C824-4DBB-9BB0-127F33F46232 Q26866036-FD791502-70CF-499E-AB2F-73270A2B3F57 Q27022847-7EB74809-2159-4CEC-B69F-80CA0B0C49B5 Q28072919-06E9035A-F032-4C79-8476-64574640FD16 Q28078942-C9D753BE-82AA-4A30-A487-11CD3263F727 Q28534277-98B7A591-C952-40E0-9191-BCC9C2DAFB9C Q28541950-A4E0DE9A-AF8A-4ED3-807B-0F54270E09E1 Q28554583-D4BC8529-C191-4959-8D4C-B8C04035A8AF Q30244674-852C581F-D3B0-45AA-B609-6A61159D3772 Q30276626-712EDAFA-ED32-4E47-92BE-8225528FC975 Q30278648-4BD9377F-63ED-46D7-B1A2-DFA9338E72B2 Q30300626-D70AF256-0330-4B08-8069-B448223DFBBA Q30371634-69B3A0E2-0F79-4720-B3F0-CCBCEC0A7335 Q30385364-84B8BC0B-4F99-4CD1-ADBA-52C22422B26F Q30405851-23157005-F4DB-4383-BBCA-E081A1041FED Q30656223-1278977E-42C0-4005-9698-5EAA38D572BB Q31083823-E66F4126-3F8A-4702-96F4-A04B86F9E3BB Q32177636-6F9C8FF3-DDEA-4C2A-826F-11CE3ADB937C Q33669456-6470BD3A-6767-4590-90B3-438F2F391B08 Q33710312-4AFF4F2A-A49E-4EF3-A471-51643D4F3841 Q33722746-92FC556F-FAAB-459F-92EF-642FB377F968 Q33754012-6DF24FF2-3044-41BD-A1EF-4EABB6EF4ED3 Q33754017-1C45138C-F0E8-4790-8081-680B420808DE Q33758771-E18D9133-724B-474C-8618-DF57491BC795 Q33759725-FDE9ACAA-7A43-4378-B64F-243FB884DBCF Q33766462-968F98F5-35DE-49F9-8416-CF21B79D1B07 Q33825388-99403BBC-8FDA-4E0D-95FD-6A98F36355F0 Q33898869-1839328A-B7CC-4ADD-88E1-FF7EF4618A3D Q33927594-08AB0081-08A8-4ADD-B4C0-D3A857C2B7FB

P2860

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

http://www.wikidata.org/entity/Q24605205

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Adjuvant radiotherapy for path ...... of a randomized clinical trial

@ast

Adjuvant radiotherapy for path ...... of a randomized clinical trial

@en

Adjuvant radiotherapy for path ...... of a randomized clinical trial

@nl

type

label

Adjuvant radiotherapy for path ...... of a randomized clinical trial

@ast

Adjuvant radiotherapy for path ...... of a randomized clinical trial

@en

Adjuvant radiotherapy for path ...... of a randomized clinical trial

@nl

prefLabel

Adjuvant radiotherapy for path ...... of a randomized clinical trial

@ast

Adjuvant radiotherapy for path ...... of a randomized clinical trial

@en

Adjuvant radiotherapy for path ...... of a randomized clinical trial

@nl

P1433

Q24605205-A1F954B6-C3E1-491F-B96C-14EF7B73BC94

P1476

Q24605205-F7927F7E-EB9A-4DEB-9FDA-AB3225A71C9B

P2093

Q24605205-0E4B6244-74AB-4482-8C79-B5F9E2187718

Q24605205-157B456E-BED0-44F9-9F67-9E8A28732E61

Q24605205-2BDFA9A3-632B-4630-A347-9496C6CCA7BC

Q24605205-50F73383-3BF7-4B86-8CB9-404891E17218

Q24605205-68C0D9B7-4407-4EB4-8D0B-F94F3FA686C2

Q24605205-76725D77-20C4-4F18-B4D9-534CC34EF103

Q24605205-835A799A-8BF7-4DE2-8594-951EA775C48C

Q24605205-99E6279D-9E84-4E2E-916B-7609BF1A3632

Q24605205-9C1CE621-5399-4A0A-AE45-B0EDF1BB0173

Q24605205-A1D400C8-14DA-4593-B818-92BF3E9E0E78

P2860

Q24605205-12CFE21E-F8E7-43E4-B3ED-D9095E9E5792

Q24605205-367DE74F-385C-4460-BC20-A495B5DE9852

Q24605205-37883046-9127-4B1A-9C6D-D42449567942

Q24605205-464B4920-C4DF-452E-A28C-3BA89EC39D7C

Q24605205-5087B485-5C32-440E-8708-EF6E3383A258

Q24605205-684E5482-2112-41DA-8F55-6C5DF9BB5B6E

Q24605205-71E8571D-ED70-4DDC-BD48-6925460AD02B

Q24605205-7EE035C8-A798-40DF-810E-EFBBC6E68D1A

Q24605205-95A2C145-0960-4788-B667-0EAD61C0760E

Q24605205-9C70A06B-DE60-4174-A7A4-FB8228E50865

P304

Q24605205-AACED196-24AC-44AF-B8AC-87BFC250F95B

P31

Q24605205-1606C7D4-944E-453A-A3B2-0277545EF466

P3181

Q24605205-F0EE7733-4DA9-470D-9D1E-1A48FE514894

P356

Q24605205-0C376DEA-B7CE-4F57-9E0A-096BF006798B

P407

Q24605205-FF5D44B3-C431-4BF4-92FB-F25C2E9D0568

P433

Q24605205-A90B6E2B-9FD0-4C8F-8BCB-19AD7D437487

P478

Q24605205-6C90FB6C-A612-4772-9F32-4565364A5933

P577

Q24605205-D7E97D2E-9EC0-45F6-AAFC-80CD4817C10F

P5875

Q24605205-3F178F62-E14D-4D6F-9E7E-5B016B4BD570

P698

Q24605205-3B64471A-FDD3-466B-BFD4-9DA99C7AE98E

P921

Q24605205-F7466FEE-B477-49A6-80FB-D057574C833E

P932

Q24605205-2BB3EAFA-CB38-4371-AF42-8201521E04D9

P3181

P356

J.JURO.2008.11.032

P1433

The Journal of Urology

P1476

Adjuvant radiotherapy for path ...... of a randomized clinical trial

@en

P2093

Catherine M Tangen

http://www.w3.org/2001/XMLSchema#string

Dean Troyer

http://www.w3.org/2001/XMLSchema#string

E David Crawford

http://www.w3.org/2001/XMLSchema#string

Edith Canby-Hagino

http://www.w3.org/2001/XMLSchema#string

Edward Messing

http://www.w3.org/2001/XMLSchema#string

Gary Miller

http://www.w3.org/2001/XMLSchema#string

Gregory Swanson

http://www.w3.org/2001/XMLSchema#string

Ian M Thompson

http://www.w3.org/2001/XMLSchema#string

Jeffrey Forman

http://www.w3.org/2001/XMLSchema#string

Jorge Paradelo

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2008

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Radical prostatectomy versus watchful waiting in early prostate cancer.

The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

The changing face of prostate cancer.

Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories.

Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

P304

956-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1772197

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.JURO.2008.11.032

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

181

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23938043

http://www.w3.org/2001/XMLSchema#string

P698

19167731

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

3510761

http://www.w3.org/2001/XMLSchema#string